Avoro Capital Advisors LLC Iveric Bio, Inc. Transaction History

Avoro Capital Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $32.8 Million - $49.5 Million	1,250,000 Added 18.38%	8,050,000 $317 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $933,500 - $1.23 Million	50,000 Added 0.74%	6,800,000 $165 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $14.7 Million - $20.4 Million	850,000 Added 14.41%	6,750,000 $145 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $11.5 Million - $22.7 Million	-1,220,000 Reduced 17.13%	5,900,000 $106 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $1.19 Million - $2.46 Million	-130,000 Reduced 1.79%	7,120,000 $68.5 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $2.07 Million - $2.82 Million	150,000 Added 2.11%	7,250,000 $121 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $4.77 Million - $11.8 Million	675,000 Added 10.51%	7,100,000 $115 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $4.69 Million - $5.92 Million	-825,000 Reduced 11.38%	6,425,000 $40.5 Million
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $601,500 - $943,500	150,000 Added 2.11%	7,250,000 $40.9 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $21.7 Million - $46.9 Million	7,100,000 New	7,100,000 $36.2 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.